Omeros (OMER) Assets Average (2011 - 2026)
Omeros recorded quarterly Assets Average of $305.9 million in Q1 2026, up 19.65% quarter-over-quarter from $255.7 million in Q4 2025, and up 19.44% year-over-year from $256.1 million in Q1 2025.
Omeros' Assets Average history runs 16 years deep, the most recent figure standing at $305.9 million for Q1 2026.
- In Q1 2026, Assets Average rose 19.44% year-over-year to $305.9 million; the TTM figure through Mar 2026 stood at $305.9 million (up 19.44% YoY), while the FY2025 annual figure was $301.4 million, down 8.03% from the prior year.
- Assets Average came in at $305.9 million for Q1 2026 at Omeros, up from $255.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $575.6 million in Q1 2023 to a low of $193.1 million in Q3 2025.
- A 5-year average of $376.8 million and a median of $394.3 million in 2022 frame the typical range for Assets Average.
- Across the five-year window, Assets Average surged 198.78% in 2022 and plunged 45.11% in 2025, its largest moves.
- Omeros' Assets Average stood at $524.3 million in 2022, then retreated by 16.9% to $435.7 million in 2023, then sank by 32.24% to $295.2 million in 2024, then dropped by 13.39% to $255.7 million in 2025, then increased by 19.65% to $305.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $305.9 million, $255.7 million, and $193.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 305.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305.90 Mn |
| Dec 31, 2025 | 255.67 Mn |
| Sep 30, 2025 | 193.14 Mn |
| Jun 30, 2025 | 217.87 Mn |
| Mar 31, 2025 | 256.12 Mn |
| Dec 31, 2024 | 295.21 Mn |
| Sep 30, 2024 | 334.82 Mn |
| Jun 30, 2024 | 396.90 Mn |
| Mar 31, 2024 | 407.88 Mn |
| Dec 31, 2023 | 435.67 Mn |
| Sep 30, 2023 | 510.25 Mn |
| Jun 30, 2023 | 543.78 Mn |
| Mar 31, 2023 | 575.55 Mn |
| Dec 31, 2022 | 524.26 Mn |
| Sep 30, 2022 | 401.59 Mn |
| Jun 30, 2022 | 357.45 Mn |
| Mar 31, 2022 | 394.27 Mn |
| Dec 31, 2021 | 271.35 Mn |
| Sep 30, 2021 | 134.41 Mn |
| Jun 30, 2021 | 153.42 Mn |
| Mar 31, 2021 | 171.24 Mn |
| Dec 31, 2020 | 204.06 Mn |
| Sep 30, 2020 | 148.88 Mn |
| Jun 30, 2020 | 94.45 Mn |
| Mar 31, 2020 | 127.59 Mn |
| Dec 31, 2019 | 114.12 Mn |
| Sep 30, 2019 | 90.51 Mn |
| Jun 30, 2019 | 95.50 Mn |
| Mar 31, 2019 | 98.59 Mn |
| Dec 31, 2018 | 85.77 Mn |
| Sep 30, 2018 | 90.98 Mn |
| Jun 30, 2018 | 97.69 Mn |
| Mar 31, 2018 | 102.68 Mn |
| Dec 31, 2017 | 120.92 Mn |
| Sep 30, 2017 | 92.94 Mn |
| Jun 30, 2017 | 59.38 Mn |
| Mar 31, 2017 | 62.84 Mn |
| Dec 31, 2016 | 70.02 Mn |
| Sep 30, 2016 | 59.44 Mn |
| Jun 30, 2016 | 41.04 Mn |
| Mar 31, 2016 | 42.48 Mn |
| Dec 31, 2015 | 45.21 Mn |
| Sep 30, 2015 | 50.03 Mn |
| Jun 30, 2015 | 66.77 Mn |
| Mar 31, 2015 | 42.87 Mn |
| Dec 31, 2014 | 18.06 Mn |
| Sep 30, 2014 | 33.14 Mn |
| Jun 30, 2014 | 48.53 Mn |
| Mar 31, 2014 | 36.30 Mn |
| Dec 31, 2013 | 14.27 Mn |
| Sep 30, 2013 | 17.54 Mn |
| Jun 30, 2013 | 20.38 Mn |
| Mar 31, 2013 | 22.13 Mn |
| Dec 31, 2012 | 29.67 Mn |
| Sep 30, 2012 | 21.41 Mn |
| Jun 30, 2012 | 15.58 Mn |
| Mar 31, 2012 | 24.04 Mn |
| Dec 31, 2011 | 30.98 Mn |
| Sep 30, 2011 | 37.97 Mn |